Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Vascular Medicine
This Article
Right arrow Free Full Text (Free PDF) Free
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Kassab, E
Right arrow Articles by Sowers, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kassab, E
Right arrow Articles by Sowers, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Vascular complications in diabetes and their prevention

E Kassab

Endocrinology, Diabetes and Hypertension, SUNY HSC at Brooklyn, Brooklyn, NY, USA

SI McFarlane

Endocrinology, Diabetes and Hypertension, SUNY HSC at Brooklyn, Brooklyn, NY, USA

JR Sowers

VA Medical Center, Brooklyn, NY, USA, jsowers{at}netmail.hscbklyn.edu

Diabetes mellitus is increasing throughout the world. Cardiovascular disease (CVD) accounts for up to 80% of excess mortality in this high-risk population. Patients with diabetes have the same CVD risk factors as those people without diabetes. However, these risk factors are much more powerful in diabetic patients. CVD risk is especially high for diabetic women, and premenopausal diabetic women lose all the protection normally afforded to them by female sex hormones. Controlled clinical trials have clearly demonstrated that rigorous treatment of blood pressure, dyslipidemia and platelet hyperaggrebility strikingly reduces CVD risk in diabetic patients. Strategies directed at interrupting the renin-angiotensin system (both tissue and systemic systems) and the use of 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors have proven to be especially beneficial for this high-risk population.

Key Words: atherosclerosis • diabetes • dyslipidemia • hypertension

Vascular Medicine, Vol. 6, No. 4, 249-255 (2001)
DOI: 10.1177/1358836X0100600409
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
I. F. Benter, M. H. M. Yousif, C. Cojocel, M. Al-Maghrebi, and D. I. Diz
Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction
Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H666 - H672.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. M Setter, R K. Campbell, and C. J Cahoon
Biochemical Pathways for Microvascular Complications of Diabetes Mellitus
Ann. Pharmacother., December 1, 2003; 37(12): 1858 - 1866.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
K. V. RAMANA, D. CHANDRA, S. SRIVASTAVA, A. BHATNAGAR, and S. K. SRIVASTAVA
Nitric oxide regulates the polyol pathway of glucose metabolism in vascular smooth muscle cells
FASEB J, March 1, 2003; 17(3): 417 - 425.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. I. McFarlane and J. R. Sowers
Aldosterone Function in Diabetes Mellitus: Effects on Cardiovascular and Renal Disease
J. Clin. Endocrinol. Metab., February 1, 2003; 88(2): 516 - 523.
[Full Text] [PDF]